"V体育官网" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2008 Apr 1;111(7):3692-700.
doi: 10.1182/blood-2007-09-110593. Epub 2007 Dec 20.

VSports在线直播 - DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL

Stéphanie Dulucq  1 , Geneviève St-Onge, Vincent Gagné, Marc Ansari, Daniel Sinnett, Damian Labuda, Albert Moghrabi, Maja Krajinovic
Affiliations
Free article

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL

Stéphanie Dulucq et al. Blood. .
Free article

Abstract (VSports app下载)

Dihydrofolate reductase (DHFR) is the major target of methotrexate (MTX), a key component in childhood acute lymphoblastic leukemia (ALL) treatment. A total of 15 polymorphisms in DHFR promoter were analyzed, and 3 sites (C-1610G/T, C-680A, and A-317G) were identified as sufficient to define observed haplotypes (tag single nucleotide polymorphisms [tagSNPs]). These polymorphisms were investigated for association with treatment response in 277 children with ALL. Lower event-free survival (EFS) was associated with homozygosity for the allele A-317 and C-1610 (P= VSports手机版. 03 and . 02), and with the haplotype *1, defined by both C-1610 and A-317 alleles (P=. 03). The haplotype *1 conferred higher transcriptional activity (P<. 01 compared with haplotypes generating minimal luciferase expression). Quantitative mRNA analysis showed higher DHFR levels for particular haplotype *1 carriers (P<. 01). The analysis combining haplotype *1 with thymidylate synthase (TS) and cyclin D1 (CCND1) genotypes previously shown to affect ALL outcome showed that the number of event-predisposing genotypes was associated with increasingly lower EFS (P<. 001). In conclusion, DHFR promoter polymorphisms are associated with worse ALL outcome, likely due to a higher DHFR expression. Combined effects among genes of the folate cycle can further accentuate differences in the response to the treatment. .

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources